Table 2.
Epidemiologic, microbiologic, and therapeutic characteristics: 20 patients (23 episodes) with UTI recurrence.
| No. | M/F | Age at recurrence (months) | Renal background pathology | Pathogen in 1st episode | Pathogen in 2nd episode | Antimicrobial prophylaxis after first UTI |
|---|---|---|---|---|---|---|
| 1 | F | 12 | E. coli | E. coli | TMP/SMX | |
| 2 | M | 1 | Proteus spp. | C. albicans | TMP/SMX | |
| 3 | F | 2 | Proteus spp. | P. aeruginosa | TMP/SMX | |
| 4 | F | 3 | E. coli | Citrobacter spp. | TMP/SMX | |
| 5 | M | 2 | Enterobacter spp. + Enterococcus spp. | E. coli | TMP/SMX | |
| 6 | F | 2 | E. coli | Enterobacter spp. | NA | |
| 7 | M | 2 | E. coli | Klebsiella spp. | NA | |
| 8 | M | 3 | E. coli | E. coli | TMP/SMX | |
| 9 | F | 3 | E. coli | E. coli | Cefuroxime-axetil | |
| 10 | M | 6 | E. coli | E. coli | TMP/SMX | |
| 11 | F | 4 | M. morganii | E. coli | TMP/SMX | |
| 12 | M | 7 | E. coli | E. coli | TMP/SMX | |
| 13 | M | 6 | E. coli | E. coli | TMP/SMX | |
| 14 | F | 11 | Proteus spp. | E. coli | NA | |
| 15 | M | 11 | Hydronephrosis | Enterobacter spp. | Enterococcus spp. | TMP/SMX |
| 16 | M | 10 | Hydronephrosis | Enterobacter spp. | Enterobacter spp. | TMP/SMX |
| 17 | M | 4 | E. coli | E. coli | NA | |
| 18.1 | M | 7 | Klebsiella spp. | Proteus spp. | TMP/SMX | |
| 18.2 | 9 | Klebsiella spp. | E. coli | TMP/SMX | ||
| 19.1 | M | 3 | Congenital megaurether, UVJ obstruction, hydronephrosis | Klebsiella spp. | S. aureus | TMP/SMX |
| 19.2 | 7 | Klebsiella spp. | C. albicans | TMP/SMX | ||
| 19.3 | 10 | Klebsiella spp. | E. coli | TMP/SMX | ||
| 20 | M | 12 | Klebsiella spp. | Klebsiella spp. | NA |
TMP/SMX, trimethoprim/sulfamethoxazole; NA, not administered; UVJ, urethero-vesicular junction.